PS
JAZZ icon

Principal Securities’s Jazz Pharmaceuticals JAZZ Stock Holding History

Principal Securities’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-279
Closed -$36.8K – 2481
2025
Q3 		$36.8K Buy
279
+25
+10% +$3K ﹤0.01% 2109
2025
Q2 		$27K Buy
254
+137
+117% +$14.9K ﹤0.01% 2179
2025
Q1 		$14.4K Hold
117
– – ﹤0.01% 2377
2024
Q4 		$14.4K Buy
117
+26
+29% +$3.06K ﹤0.01% 2373
2024
Q3 		$10.1K Sell
91
-10
-10% -$1.1K ﹤0.01% 2435
2024
Q2 		$10.8K Sell
101
-48
-32% -$5.28K ﹤0.01% 2350
2024
Q1 		$17.9K Buy
149
+13
+10% +$1.59K ﹤0.01% 2057
2023
Q4 		$16.7K Buy
+136
New +$17K ﹤0.01% 2019

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Principal Securities's JAZZ Position: Q4 2025 in Review

Principal Securities sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 279 shares — an estimated $36.8K sold.

Principal Securities first reported a position in JAZZ in Q4 2023 and held it in 8 quarters. The position peaked at $36.8K in Q3 2025. 573 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

  • Principal Securities reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 279 Jazz Pharmaceuticals shares in Q4 2025, an estimated $36.8K.
  • Principal Securities first reported a position in Jazz Pharmaceuticals in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Jazz Pharmaceuticals position peaked at $36.8K in Q3 2025.
  • 573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.